Healthcare provider profile · identity verified

Hector Luis Martinez, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · PONCE, PR · NPI 1164476982

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Hector Luis Martinez, M.D. received $6,345.89 in general payments during 2025 across 5 reported records.

Abbott Laboratories accounted for 97.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$6,345.89

5 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Abbott Laboratories	Unresolved — no canonical attribution shown	$6,200.00	97.7%	2	2025
Boston Scientific Corporation	Unresolved — no canonical attribution shown	$124.49	2.0%	2	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$21.40	0.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Consulting Fee	$6,200.00	2
Food and Beverage	$145.89	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
SUPERA Normalized: supera	Device	Abbott Laboratories	$6,200.00	2	2025
Source payment records 2025-05-06 · Abbott Laboratories · $1,400.00 · Open Payments source 2025-05-06 · Abbott Laboratories · $4,800.00 · Open Payments source
General - Therapies Normalized: general therapies	Device	Boston Scientific Corporation	$70.94	1	2025
Source payment records 2025-09-12 · Boston Scientific Corporation · $70.94 · Open Payments source
CrossBoss Normalized: crossboss	Device	Boston Scientific Corporation	$53.55	1	2025
Source payment records 2025-10-06 · Boston Scientific Corporation · $53.55 · Open Payments source
ELIQUIS Normalized: eliquis	Drug	E.R. Squibb & Sons, L.L.C.	$21.40	1	2025
Source payment records 2025-02-05 · E.R. Squibb & Sons, L.L.C. · $21.40 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	74	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	74	29

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	862	212
Losartan Potassium	Losartan Potassium	543	128
Metformin Hcl	Metformin Hcl	506	93
Simvastatin	Simvastatin	494	92
Famotidine	Famotidine	423	90
Omeprazole	Omeprazole	409	67
Gabapentin	Gabapentin	397	72
Metoprolol Succinate	Metoprolol Succinate	335	87
Lisinopril	Lisinopril	330	79
Clopidogrel	Clopidogrel Bisulfate	284	102
Synthroid	Levothyroxine Sodium	282	49
Tamsulosin Hcl	Tamsulosin Hcl	261	61
Amlodipine Besylate	Amlodipine Besylate	252	65
Levothyroxine Sodium	Levothyroxine Sodium	248	50
Pantoprazole Sodium	Pantoprazole Sodium	210	49
Hydrochlorothiazide	Hydrochlorothiazide	204	42
Furosemide	Furosemide	198	78
Metoprolol Tartrate	Metoprolol Tartrate	188	45
Glipizide	Glipizide	152	29
Glimepiride	Glimepiride	149	27
Rosuvastatin Calcium	Rosuvastatin Calcium	131	30
Montelukast Sodium	Montelukast Sodium	110	26
Donepezil Hcl	Donepezil Hcl	105	27
Carvedilol	Carvedilol	104	51
Spironolactone	Spironolactone	88	33
Enalapril Maleate	Enalapril Maleate	86	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	86	15
Pioglitazone Hcl	Pioglitazone Hcl	86	19
Doxazosin Mesylate	Doxazosin Mesylate	83	15
Fenofibrate	Fenofibrate	81	13
Finasteride	Finasteride	80	20
Latanoprost	Latanoprost	75	suppressed
Eliquis	Apixaban	74	29
Temazepam	Temazepam	71	16
Atenolol	Atenolol	68	11
Lorazepam	Lorazepam	66	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	64	suppressed
Fluticasone Propionate	Fluticasone Propionate	61	16
Meclizine Hcl	Meclizine Hcl	57	13
Alendronate Sodium	Alendronate Sodium	55	12
Clonazepam	Clonazepam	55	16
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	54	11
Lantus	Insulin Glargine,hum.Rec.Anlog	53	27
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	52	13
Ezetimibe	Ezetimibe	51	suppressed
Sertraline Hcl	Sertraline Hcl	51	18
Meloxicam	Meloxicam	50	12
Albuterol Sulfate Hfa	Albuterol Sulfate	49	15
Alprazolam	Alprazolam	49	suppressed
Pravastatin Sodium	Pravastatin Sodium	48	suppressed
Diclofenac Sodium	Diclofenac Sodium	47	15
Irbesartan	Irbesartan	46	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	44	43
Insulin Syringe	Syringe And Needle,insulin,1ml	44	11
Duloxetine Hcl	Duloxetine Hcl	41	11
Nabumetone	Nabumetone	41	18
Prednisone	Prednisone	41	19
Warfarin Sodium	Warfarin Sodium	41	suppressed
Amiodarone Hcl	Amiodarone Hcl	40	26
Isosorbide Mononitrate Er	Isosorbide Mononitrate	40	36
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	39	13
Janumet	Sitagliptin Phos/Metformin Hcl	39	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	38	suppressed
Lansoprazole	Lansoprazole	36	suppressed
Nifedipine Er	Nifedipine	36	13
Sucralfate	Sucralfate	35	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	34	33
Azithromycin	Azithromycin	34	33
Sulindac	Sulindac	34	suppressed
Tramadol Hcl	Tramadol Hcl	34	suppressed
Xarelto	Rivaroxaban	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	33	suppressed
Valsartan	Valsartan	33	suppressed
Pregabalin	Pregabalin	32	suppressed
Digoxin	Digoxin	31	suppressed
Hydralazine Hcl	Hydralazine Hcl	31	25
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	30	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	29	suppressed
Cilostazol	Cilostazol	29	12
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Entresto	Sacubitril/Valsartan	27	16
Jardiance	Empagliflozin	27	22
Verapamil Sr	Verapamil Hcl	27	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	26	suppressed
Memantine Hcl	Memantine Hcl	26	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	26	suppressed
Allopurinol	Allopurinol	24	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	23	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Tradjenta	Linagliptin	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Glipizide Er	Glipizide	20	suppressed
Humulin N	Insulin Nph Human Isophane	20	suppressed
Brilinta	Ticagrelor	19	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Naproxen Sodium	Naproxen Sodium	19	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Doxepin Hcl	Doxepin Hcl	18	suppressed
Orphenadrine Citrate Er	Orphenadrine Citrate	18	13
Risperidone	Risperidone	18	11
Sildenafil Citrate	Sildenafil Citrate	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Insulin Glargine	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Etodolac	Etodolac	16	suppressed
Methylprednisolone	Methylprednisolone	16	14
Tolterodine Tartrate Er	Tolterodine Tartrate	16	suppressed
Trazodone Hcl	Trazodone Hcl	16	suppressed
Calcitriol	Calcitriol	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Azathioprine	Azathioprine	14	suppressed
Clindamycin Hcl	Clindamycin Hcl	14	12
Insulin Lispro	Insulin Lispro	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	11
Cefadroxil	Cefadroxil	13	13
Clotrimazole	Clotrimazole	13	suppressed
Dexlansoprazole Dr	Dexlansoprazole	13	suppressed
Humalog	Insulin Lispro	13	13
Humalog Mix 50-50 Kwikpen	Insulin Lispro Protamin/Lispro	13	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	12	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	12	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	12	suppressed
Livalo	Pitavastatin Calcium	12	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Ramipril	Ramipril	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Dexamethasone	Dexamethasone	11	11
Dutasteride	Dutasteride	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Naproxen	Naproxen	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$6,345.89 · 5 records	Abbott Laboratories	CrossBoss, ELIQUIS, General - Therapies, SUPERA	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error